Despite comprising a very small proportion of circulating blood leukocytes, basophils are
potent immune effector cells. The high-affinity receptor for IgE (FcɛRI) is expressed on the …

All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE,
supported by comparative preclinical data, offers the potential for enhanced effector cell …

Background Survival rates for ovarian cancer remain poor, and monitoring and prediction of
therapeutic response may benefit from additional markers. Ovarian cancers frequently …

Immunoglobulin E (IgE) antibodies are well known for their role in allergic diseases and for
contributions to antiparasitic immune responses. Properties of this antibody class that …

Outcomes for half of patients with melanoma remain poor despite standard-of-care
checkpoint inhibitor therapies. The prevalence of the melanoma-associated antigen …

Basophils are involved in manifestations of hypersensitivity, however, the current
understanding of their propensity for activation and their prognostic value in cancer patients …

A correct diagnosis of drug hypersensitivity reactions (DHRs) is very important for both the
patient and health system. However, DHRs diagnosis is complex, time consuming, requires …

Simple Summary When activated by tumour antigen-specific IgEs, monocytes may
contribute to the restriction of cancer growth in animal models of cancer. In this study, we …

Background Cancer immunotherapy with monoclonal antibodies and chimeric antigen
receptor (CAR) T cell therapies can benefit from selection of new targets with high levels of …

Hypersensitivity reactions to drugs are increasing worldwide. They display a large degree of
variability in the immunological mechanisms involved, which impacts both disease severity …